Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Amgen enters definitive merger agreement

Jan. 30, 2012

Targovax secures funding for cancer vaccine research

Jan. 26, 2012

ImmunoCellular Therapeutics provides update on phase III ICT-107 study

Jan. 24, 2012

Interim results reported from phase I/IIa ensituximab trial

Jan. 24, 2012

Enrollment opens in phase III PRESENT study of NeuVax

Jan. 23, 2012

Fifth Merrimack Pharmaceuticals program advances to clinic

Jan. 16, 2012

Treatment begins in phase II study of Advaxis' ADXS-HPV

Jan. 16, 2012

First-in-human data disclosed on ALT-801

Jan. 11, 2012

Circadian Technologies initiates first clinical study of VGX-100

Jan. 9, 2012

Celldex begins phase II study of rindopepimut

Jan. 5, 2012

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...